Azarga

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Instructions for use:

1. Release form and composition
2. Indications for use
3. Contraindications
4. Method of application and dosage
5. Side effects
6. Special instructions
7. Drug interactions
8. Analogs
9. Terms and conditions of storage
10. Terms of dispensing from pharmacies

Prices in online pharmacies:

from 746 rub.

Buy

Azarga is a combined antiglaucoma agent containing a carbonic anhydrase II inhibitor and a non-selective beta-adrenergic receptor blocker.

Release form and composition

Dosage form - eye drops: a homogeneous suspension of almost white or white color (5 ml in plastic dropper bottles "Droptainer ™", in a cardboard box 1 bottle).

1 ml drops contain:

Active ingredients: brinzolamide - 10 mg; timolol (in the form of maleate) - 5 mg;
Auxiliary components: benzalkonium chloride (50% solution), sodium chloride, sodium hydroxide, disodium edetate, tyloxapol, mannitol, purified water.

Indications for use

Azarga is used to reduce increased intraocular pressure in intraocular hypertension and open-angle glaucoma in case of ineffectiveness of monotherapy.

Contraindications

Absolute:

Closed-angle glaucoma;
Severe allergic rhinitis;
Bronchial hyperreactivity;
Chronic obstructive pulmonary disease of severe course;
Bronchial asthma (including history);
Cardiogenic shock;
Severe heart failure;
Atrioventricular block II-III degree;
Sinus bradycardia;
Severe renal failure (creatinine clearance less than 30 ml / minute);
Hyperchloremic acidosis;
Age under 18;
Pregnancy and lactation period;
Concomitant use of oral carbonic anhydrase inhibitors;
Hypersensitivity to the components of Azarga, sulfonamides or beta-blockers.

Relative (drops are used with caution):

Hyperthyroidism;
Prinzmetal's angina;
Arterial hypotension and cardiovascular disease;
Central and peripheral circulatory disorders;
Pseudoexfoliative glaucoma;
Pigmented glaucoma;
Hypoglycemic tendency;
Diabetes mellitus, especially labile course;
Myasthenia gravis;
Violations of acid-base balance;
Liver failure;
Atopy or severe anaphylactic reactions to various allergens in history.

Method of administration and dosage

Azarga is applied topically. Shake the bottle before use.

The drug is prescribed 1 drop in the conjunctival sac of the eye 2 times a day.

To reduce the risk of systemic side effects after instillation, it is recommended to gently press for 1-2 minutes with a finger on the projection area of the lacrimal sacs at the inner corner of the eye (this helps to reduce the systemic absorption of the drug).

In case of skipping the next instillation, it is necessary to continue using the drug from the next dose in accordance with the schedule. The recommended daily dose should not be exceeded.

In the case of the previous use of another antiglaucoma drug, you need to start using Azarga the next day after canceling the previous drug.

Side effects

Gradation of side effects from organs and systems on the following scale: often - from> 1/100 to 1/1000 to <1/100; the frequency is unknown - it is not possible to estimate the frequency reliably or to establish a direct connection with the drug intake:

From the nervous system and psyche: often - dysgeusia ¹, infrequently - insomnia ¹, frequency unknown - headache ¹, depression ¹, dizziness ^1.2, cerebrovascular disorder ², cerebral ischemia ², fainting ², memory loss ², increased symptoms and symptoms of myasthenia gravis ², nightmares ^2,3, paresthesias ^2,3, nocturnal nervousness ³, apathy ³, memory impairment ³, amnesia ³, drowsiness ³, depressed mood³, hypesthesia ³, tremor ³, ageusia ³, motor dysfunctions ³, decreased libido ³;
From the side of the organ of vision: often - eye pain ¹, blurred vision ¹, eye irritation ¹; infrequently - dry eye syndrome ¹, photophobia ¹, punctate keratitis ¹, eye redness ¹, conjunctival hyperemia ¹, scleral hyperemia ¹, increased lacrimation ¹, eye discharge ¹, sensation of a foreign body in the eyes ¹, eyelid erythema ¹, effusion in anterior chamber of the eye ¹, corneal erosion ¹, itching in the eye ^1.3; frequency unknown - visual impairment ¹, eyelid edema ¹, decreased sensitivity of the cornea ², ptosis ², detachment of the choroid after filtering surgery ², keratitis ^2.3, decreased visual acuity ^2.3, diplopia ^2.3, visual impairment ³, deposits in the eye ³, corneal epithelial defect ³, increased excavation of the optic nerve head ³, madarosis ³, increased lacrimation ³, allergic reactions of the eye ³, pterygium ³, increased intraocular pressure ³, swelling of the eyes ³, discomfort in the eye ³, corneal epithelium disorder ³, conjunctivitis ³, keratopathy ³, meibomian gland inflammation ³, scleral pigmentation ³, decreased visual contrast ³, corneal staining ³, “dry” keratoconjunctivitis ³, photopsy ³, ocular hypesthesia ³, disorders eyelid ³, asthenopia ³, corneal edema ³, crusting at the edges of the eyelids ³, blepharitis ³, subconjunctival cyst ³;
Infectious and parasitic diseases: frequency unknown - rhinitis ³, pharyngitis ³, nasopharyngitis ³, sinusitis ³;
From the side of the blood and lymphatic system: the frequency is unknown - an increase in the content of chlorides in the blood ³, a decrease in the number of erythrocytes ³;
Immune system disorders: frequency unknown - hypersensitivity ¹, systemic allergic reactions ² (including angioedema), urticaria ², pruritus ², local and generalized rash ², systemic lupus erythematosus ², anaphylaxis ³;
On the part of the organ of hearing: the frequency is unknown - ringing in the ears ³, vertigo ³;
From the side of the cardiovascular system: infrequently - lowering blood pressure ¹; frequency unknown - increased blood pressure ¹, cold hands and feet ², edema ², hypotension ², chest pain ², AV block ², Raynaud's phenomenon ², heart failure ², chronic heart failure ², cardiac arrest ², bradycardia ^{2, 3}, palpitations ^2.3, arrhythmia ^2.3, hypertension ³, tachycardia ³, angina pectoris ³, increased heart rate ³, irregular heart rate ³, cardio-respiratory distress syndrome ³;
From the respiratory system, chest and mediastinal organs: infrequently - cough ¹; frequency unknown - shortness of breath ¹, epistaxis ¹, asthma ¹, bronchospasm ² (mainly in patients with a history of bronchospastic disease), nasal congestion ³, nasal dryness ³, sneezing ³, rhinorrhea ³, laryngeal irritation ³, pharyngolaryngitis pain ³, congestion upper respiratory tract ³, bronchial hyperreactivity ³, postnasal drip syndrome ³;
From the gastrointestinal tract: often - dysgeusia after instillation ^1,3 (bitter or unusual taste in the mouth); frequency unknown - dry mouth ¹, upper abdominal pain ^1.3, nausea ^1.3, diarrhea ^1.3, abdominal pain ², dyspepsia ^2.3, vomiting ^2.3, discomfort in the abdominal cavity and stomach ³, esophagitis ³, gastrointestinal upset ³, increased peristalsis ³, flatulence ³, hypoesthesia and paresthesia of the oral cavity ³;
Skin and subcutaneous tissue disorders: frequency unknown - rash ¹, alopecia ¹, erythema ^1.3, psoriasiform rash or exacerbation of psoriasis ², maculopapular rash ^2.3, skin tightening ³, urticaria ³, dermatitis ³, generalized itching ³;
Musculoskeletal and connective tissue disorders: frequency unknown - myalgia ¹, pain in the extremities ³, back pain ³, arthralgia ³, muscle spasms ³;
On the part of the kidneys and urinary tract: the frequency is unknown - pollakiuria ³, pain in the kidney area ³;
On the part of the genitals and breast: the frequency is unknown - decreased libido ², sexual dysfunction ², erectile dysfunction ³;
Others: frequency unknown - chest pain ¹, fatigue ^1.2, asthenia ^2.3, pain ³, irritability ³, abnormal sensations ³, chest discomfort ³, malaise ³, anxiety ³, peripheral edema ³;
Laboratory and instrumental data: the frequency is unknown - an increase in the content of lactate dehydrogenase and potassium in the blood ¹.

Notes:

¹ Adverse reactions observed with Azarga.

² Adverse reactions that have occurred with timolol monotherapy.

³ Adverse reactions that have been observed with brinzolamide monotherapy.

special instructions

Even with local use, timolol can cause the same side effects from the respiratory and cardiovascular systems as systemic beta-blockers. For this reason, before prescribing the drug and during its use, the patient's condition should be monitored. There are cases of severe cardiovascular and respiratory disorders, including deaths, due to bronchospasm in patients with bronchial asthma and death from heart failure.

Before a planned operation with the use of general anesthesia, it is necessary to stop using Azarga in 48 hours, because timolol, like all beta-blockers, can reduce the sensitivity of the myocardium to sympathetic stimulation necessary for the heart to work.

Benzalkonium chloride, which is part of the drug (as a preservative), can cause eye irritation and discoloration of soft contact lenses. Lenses should be removed before instillation and reinstalled no earlier than 15 minutes later.

Benzalkonium chloride can cause punctate keratopathy and / or toxic ulcerative keratopathy, and brinzolamide can disrupt corneal hydration, therefore, with long-term treatment, it is necessary to monitor the patient's general well-being, including the state of his cornea. Special supervision is required for patients with diabetes mellitus, corneal abnormalities and dystrophy.

Care should be taken when instilling: do not touch the eye and other surfaces with the dropper to avoid contamination of the drug. Close the bottle after each use.

Due to a possible decrease in visual clarity immediately after instillation, it is recommended to refrain from driving and performing potentially dangerous types of work that require increased attention.

Oral carbonic anhydrase inhibitors may interfere with reaction rates and the ability to concentrate in the elderly. This effect must be taken into account when prescribing Azarga, since its components (including the carbonic anhydrase inhibitor brinzolamide) penetrate the systemic circulation.

Drug interactions

Studies on the interaction of Azarga with other drugs have not been conducted.

Oral carbonic anhydrase inhibitors should not be administered concurrently, as there is a risk of increased systemic adverse reactions.

Care should be taken to concomitantly use drugs that inhibit the CYP3A4 isoenzyme, such as ritonavir, clotrimazole, troleandomycin, itraconazole and ketoconazole.

With the simultaneous use of CYP2D6 inhibitors (for example, quinidine or cimetidine), it is possible to increase the systemic effect of timolol (decrease in heart rate).

There is a possibility of increased hypotensive action and / or the development of severe bradycardia with the combined use of Azarga with oral calcium channel blockers, antiarrhythmic drugs, beta-blockers, cardiac glycosides, parasympathomimetics, guanethidine.

Timolol can mask the symptoms of hypoglycemia and enhance the hypoglycemic effect of antidiabetic agents.

After abrupt withdrawal of clonidine, timolol may increase hypertension.

If it is necessary to use other local ophthalmic agents between instillations, at least 15-minute intervals should be observed.

Analogs

Analogs of Azarga are: Arutimol, Okumed, Oftan, Timoptik.

Terms and conditions of storage

Keep out of the reach of children at a temperature of 2-30 ºС.

Shelf life - 2 years, after the first opening of the bottle - 4 weeks.

Terms of dispensing from pharmacies

Dispensed by prescription.

Azarga: prices in online pharmacies

Drug name

Price

Pharmacy

Azarga eye drops 5 ml 1 pc.

746 RUB

Buy

Azarga eye drops 5ml

RUB 900

Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!